Sergiy V Kushchayev1, Yevgeniya S Kushchayeva2, Philip C Wiener1, Adrienne C Scheck3, Behnam Badie4, Mark C Preul5. 1. Neurosurgery Research Laboratory, Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. 2. Neurosurgery Research Laboratory, Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA; Department of Surgery, Medstar Washington Hospital Center, Washington, DC, USA. 3. Neuro-oncology Research Laboratory, Division of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. 4. Division of Neurosurgery, Department of Surgery, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA. 5. Neurosurgery Research Laboratory, Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Electronic address: neuropub@chw.edu.
Abstract
OBJECTIVE: Monocyte-derived cells of the brain (MDCB) are a diverse group of functional immune cells that are also highly abundant in gliomas. There is growing evidence that MDCB play essential roles in the pathogenesis of gliomas. The aim of this review was to collate and systematize contemporary knowledge about these cells as they relate to glioma progression and antiglioblastoma therapeutic modalities with a view toward improved effectiveness of therapy. METHODS: We reviewed relevant studies to construct a summary of different MDCB subpopulations in steady state and in malignant gliomas and discuss their role in the development of malignant gliomas and potential future therapies. RESULTS: Current studies suggest that MDCB subsets display different phenotypes and differentiation potentials depending on their milieu in the brain and exposure to tumoral influences. MDCB possess specific and unique functions, including those that are protumoral and those that are antitumoral. CONCLUSIONS: Elucidating the role of mononuclear-derived cells associated with gliomas is crucial in designing novel immunotherapy strategies. Much progress is needed to characterize markers to identify cell subsets and their specific regulatory roles. Investigation of MDCB can be clinically relevant. Specific MDCB populations potentially can be used for glioma therapy as a target or as cell vehicles that might deliver cytotoxic substances or processes to the glioma microenvironment.
OBJECTIVE: Monocyte-derived cells of the brain (MDCB) are a diverse group of functional immune cells that are also highly abundant in gliomas. There is growing evidence that MDCB play essential roles in the pathogenesis of gliomas. The aim of this review was to collate and systematize contemporary knowledge about these cells as they relate to glioma progression and antiglioblastoma therapeutic modalities with a view toward improved effectiveness of therapy. METHODS: We reviewed relevant studies to construct a summary of different MDCB subpopulations in steady state and in malignant gliomas and discuss their role in the development of malignant gliomas and potential future therapies. RESULTS: Current studies suggest that MDCB subsets display different phenotypes and differentiation potentials depending on their milieu in the brain and exposure to tumoral influences. MDCB possess specific and unique functions, including those that are protumoral and those that are antitumoral. CONCLUSIONS: Elucidating the role of mononuclear-derived cells associated with gliomas is crucial in designing novel immunotherapy strategies. Much progress is needed to characterize markers to identify cell subsets and their specific regulatory roles. Investigation of MDCB can be clinically relevant. Specific MDCB populations potentially can be used for glioma therapy as a target or as cell vehicles that might deliver cytotoxic substances or processes to the glioma microenvironment.
Authors: Kristan E van der Vos; Erik R Abels; Xuan Zhang; Charles Lai; Esteban Carrizosa; Derek Oakley; Shilpa Prabhakar; Osama Mardini; Matheus H W Crommentuijn; Johan Skog; Anna M Krichevsky; Anat Stemmer-Rachamimov; Thorsten R Mempel; Joseph El Khoury; Suzanne E Hickman; Xandra O Breakefield Journal: Neuro Oncol Date: 2015-10-03 Impact factor: 12.300
Authors: Susan Brandenburg; Kati Turkowski; Annett Mueller; Yordan T Radev; Sabine Seidlitz; Peter Vajkoczy Journal: Immunol Res Date: 2017-06 Impact factor: 2.829
Authors: Steen J Madsen; Catherine Christie; Seok Jin Hong; Anthony Trinidad; Qian Peng; Francisco A Uzal; Henry Hirschberg Journal: Lasers Med Sci Date: 2015-03-21 Impact factor: 3.161
Authors: Michael Zhang; Gregor Hutter; Suzana A Kahn; Tej D Azad; Sharareh Gholamin; Chelsea Y Xu; Jie Liu; Achal S Achrol; Chase Richard; Pia Sommerkamp; Matthew Kenneth Schoen; Melissa N McCracken; Ravi Majeti; Irving Weissman; Siddhartha S Mitra; Samuel H Cheshier Journal: PLoS One Date: 2016-04-19 Impact factor: 3.240